Combination therapy for relapsed follicular lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, lenalidomide) plus an immunotherapy drug (tislelizumab) for people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older with relapsed or refractory follicular lymphoma (a type of slow-growing lymphoma that has come back or not responded to treatment).
- You have had at least two previous treatments, including one with a drug like rituximab (an antibody therapy).
- You are able to do daily activities with little to no help (ECOG performance status 0 or 1).
- Your liver, kidneys, and blood counts are working well enough as shown by recent lab tests.
- If you or your partner could become pregnant, you must agree to use effective birth control or avoid pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug, odronextamab, combined with lenalidomide works better than the current standard, rituximab combined with lenalidomide, for people whose follicular or marginal zone lymphoma has come back or not responded to prior treatment. It aims to see which combo is safer and more effective.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
This trial tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) for people newly diagnosed with follicular lymphoma. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This study compares two drug combinations for people newly diagnosed with follicular lymphoma. One group gets zanubrutinib plus lenalidomide, and the other gets lenalidomide plus rituximab. The goal is to see which combination works better with acceptable side effects.
Hear when a new Relapsed/Refractory Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.